GB201809699D0 - IL-11 antibodies - Google Patents

IL-11 antibodies

Info

Publication number
GB201809699D0
GB201809699D0 GBGB1809699.0A GB201809699A GB201809699D0 GB 201809699 D0 GB201809699 D0 GB 201809699D0 GB 201809699 A GB201809699 A GB 201809699A GB 201809699 D0 GB201809699 D0 GB 201809699D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1809699.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enleofen Bio Pte Ltd
National University of Singapore
Singapore Health Services Pte Ltd
Original Assignee
Enleofen Bio Pte Ltd
National University of Singapore
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enleofen Bio Pte Ltd, National University of Singapore, Singapore Health Services Pte Ltd filed Critical Enleofen Bio Pte Ltd
Priority to GBGB1809699.0A priority Critical patent/GB201809699D0/en
Publication of GB201809699D0 publication Critical patent/GB201809699D0/en
Priority to PE2020001992A priority patent/PE20211498A1/es
Priority to US16/440,840 priority patent/US11084874B2/en
Priority to SG11202011782XA priority patent/SG11202011782XA/en
Priority to JP2020568955A priority patent/JP2021535733A/ja
Priority to CN201980054506.1A priority patent/CN113056481A/zh
Priority to JOP/2020/0309A priority patent/JOP20200309A1/ar
Priority to TW108120516A priority patent/TW202003560A/zh
Priority to MA052884A priority patent/MA52884A/fr
Priority to CR20210009A priority patent/CR20210009A/es
Priority to CA3102483A priority patent/CA3102483A1/en
Priority to BR112020025443-6A priority patent/BR112020025443A2/pt
Priority to MX2020013583A priority patent/MX2020013583A/es
Priority to KR1020217000825A priority patent/KR20210031690A/ko
Priority to PCT/EP2019/065598 priority patent/WO2019238882A1/en
Priority to EA202092668A priority patent/EA202092668A1/ru
Priority to AU2019286795A priority patent/AU2019286795B2/en
Priority to EP19734285.0A priority patent/EP3807314A1/en
Priority to CONC2020/0015383A priority patent/CO2020015383A2/es
Priority to IL279356A priority patent/IL279356A/en
Priority to DO2020000245A priority patent/DOP2020000245A/es
Priority to CL2020003223A priority patent/CL2020003223A1/es
Priority to PH12020552232A priority patent/PH12020552232A1/en
Priority to SA520420801A priority patent/SA520420801B1/ar
Priority to ECSENADI2021695A priority patent/ECSP21000695A/es
Priority to US17/212,456 priority patent/US20210230266A1/en
Priority to US18/592,746 priority patent/US20240270837A1/en
Priority to US18/592,665 priority patent/US20240190953A1/en
Priority to JP2024076402A priority patent/JP2024105466A/ja
Priority to DO2024000220A priority patent/DOP2024000220A/es
Priority to AU2026201704A priority patent/AU2026201704A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
GBGB1809699.0A 2018-06-13 2018-06-13 IL-11 antibodies Ceased GB201809699D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB1809699.0A GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies
EP19734285.0A EP3807314A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies
PCT/EP2019/065598 WO2019238882A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies
EA202092668A EA202092668A1 (ru) 2018-06-13 2019-06-13 Антитела к ил-11
SG11202011782XA SG11202011782XA (en) 2018-06-13 2019-06-13 Il-11 antibodies
JP2020568955A JP2021535733A (ja) 2018-06-13 2019-06-13 Ｉｌ−１１抗体
CN201980054506.1A CN113056481A (zh) 2018-06-13 2019-06-13 Il-11抗体
JOP/2020/0309A JOP20200309A1 (ar) 2018-06-13 2019-06-13 أجسام مضادة لـ il-11
TW108120516A TW202003560A (zh) 2018-06-13 2019-06-13 Il-11抗體
MA052884A MA52884A (fr) 2018-06-13 2019-06-13 Anticorps anti-il-11
CR20210009A CR20210009A (es) 2018-06-13 2019-06-13 Anticuerpos dirigidos contra il-11
US16/440,840 US11084874B2 (en) 2018-06-13 2019-06-13 IL-11 antibodies
BR112020025443-6A BR112020025443A2 (pt) 2018-06-13 2019-06-13 Anticorpos il-11
MX2020013583A MX2020013583A (es) 2018-06-13 2019-06-13 Anticuerpos il-11.
KR1020217000825A KR20210031690A (ko) 2018-06-13 2019-06-13 Il-11 항체
PE2020001992A PE20211498A1 (es) 2018-06-13 2019-06-13 Anticuerpos dirigidos contra il-11
AU2019286795A AU2019286795B2 (en) 2018-06-13 2019-06-13 IL-11 antibodies
CA3102483A CA3102483A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies
CONC2020/0015383A CO2020015383A2 (es) 2018-06-13 2020-12-09 Anticuerpos dirigidos contra il-11
IL279356A IL279356A (en) 2018-06-13 2020-12-10 IL-11 antibodies
DO2020000245A DOP2020000245A (es) 2018-06-13 2020-12-11 Anticuerpos il-11
CL2020003223A CL2020003223A1 (es) 2018-06-13 2020-12-11 Anticuerpos il-11
PH12020552232A PH12020552232A1 (en) 2018-06-13 2020-12-13 IL-11 Antibodies
SA520420801A SA520420801B1 (ar) 2018-06-13 2020-12-13 أil جسام مضادة لـ -11
ECSENADI2021695A ECSP21000695A (es) 2018-06-13 2021-01-06 Anticuerpos dirigidos contra il-11
US17/212,456 US20210230266A1 (en) 2018-06-13 2021-03-25 Il-11 antibodies
US18/592,746 US20240270837A1 (en) 2018-06-13 2024-03-01 Il-11 antibodies
US18/592,665 US20240190953A1 (en) 2018-06-13 2024-03-01 Il-11 antibodies
JP2024076402A JP2024105466A (ja) 2018-06-13 2024-05-09 Ｉｌ－１１抗体
DO2024000220A DOP2024000220A (es) 2018-06-13 2024-10-29 Anticuerpos il-11
AU2026201704A AU2026201704A1 (en) 2018-06-13 2026-03-05 IL-11 antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1809699.0A GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies

Publications (1)

Publication Number Publication Date
GB201809699D0 true GB201809699D0 (en) 2018-08-01

Family

ID=63042160

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1809699.0A Ceased GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies

Country Status (25)

Country Link
US (4) US11084874B2 (https=)
EP (1) EP3807314A1 (https=)
JP (2) JP2021535733A (https=)
KR (1) KR20210031690A (https=)
CN (1) CN113056481A (https=)
AU (2) AU2019286795B2 (https=)
BR (1) BR112020025443A2 (https=)
CA (1) CA3102483A1 (https=)
CL (1) CL2020003223A1 (https=)
CO (1) CO2020015383A2 (https=)
CR (1) CR20210009A (https=)
DO (2) DOP2020000245A (https=)
EA (1) EA202092668A1 (https=)
EC (1) ECSP21000695A (https=)
GB (1) GB201809699D0 (https=)
IL (1) IL279356A (https=)
JO (1) JOP20200309A1 (https=)
MA (1) MA52884A (https=)
MX (1) MX2020013583A (https=)
PE (1) PE20211498A1 (https=)
PH (1) PH12020552232A1 (https=)
SA (1) SA520420801B1 (https=)
SG (1) SG11202011782XA (https=)
TW (1) TW202003560A (https=)
WO (1) WO2019238882A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
AU2017378111A1 (en) 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
TWI858005B (zh) * 2019-01-21 2024-10-11 新加坡商新加坡保健服務私人有限公司 肝毒性之治療
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
CN114364693A (zh) 2019-05-03 2022-04-15 新加坡保健服务私人有限公司 代谢性疾病的治疗和预防
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
CN116601169A (zh) * 2020-07-20 2023-08-15 生物综合治疗有限公司 针对马尔堡病毒的广泛中和结合分子
WO2022033538A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 Il-11的抗体及其应用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
MX2023009946A (es) 2021-02-26 2023-09-04 Bayer Ag Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal.
US20250092126A1 (en) 2021-07-26 2025-03-20 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
JP2024532709A (ja) * 2021-08-12 2024-09-10 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｉｌ－１１ヒト化抗体及びその用途
KR20240067079A (ko) 2021-08-30 2024-05-16 라센 테라퓨틱스 1, 인코포레이티드 항-IL-11Rα 항체
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN116891528A (zh) 2022-01-29 2023-10-17 迈威(上海)生物科技股份有限公司 一种抗白介素-11的抗体及其应用
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN118307670A (zh) 2023-01-06 2024-07-09 广东东阳光药业股份有限公司 抗il-11细胞因子人源化抗体
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518761B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2025026206A1 (zh) * 2023-07-28 2025-02-06 迈威(上海)生物科技股份有限公司 抗白介素-11抗体在制备肿瘤治疗药物中的应用
WO2025108343A1 (zh) * 2023-11-22 2025-05-30 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白
WO2025146029A1 (zh) * 2024-01-02 2025-07-10 上海华奥泰生物药业股份有限公司 靶向il-11和tslp的多特异性分子
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026001793A1 (zh) * 2024-06-27 2026-01-02 上海华奥泰生物药业股份有限公司 靶向il-11的抗原结合蛋白及其用途
CN119119262B (zh) * 2024-08-02 2025-05-02 杭州曼迪生物科技有限公司 一种干细胞冻干粉及其在制备药物或者化妆品中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335336B (https=) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) * 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
AU2017378111A1 (en) 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
RU2016151730A (ru) * 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11

Also Published As

Publication number Publication date
US20240270837A1 (en) 2024-08-15
CN113056481A (zh) 2021-06-29
US20210230266A1 (en) 2021-07-29
MA52884A (fr) 2021-04-21
JP2024105466A (ja) 2024-08-06
ECSP21000695A (es) 2021-03-31
KR20210031690A (ko) 2021-03-22
SA520420801B1 (ar) 2023-12-07
CO2020015383A2 (es) 2021-04-19
CL2020003223A1 (es) 2021-07-30
PE20211498A1 (es) 2021-08-11
EP3807314A1 (en) 2021-04-21
IL279356A (en) 2021-01-31
AU2019286795B2 (en) 2026-03-12
AU2026201704A1 (en) 2026-03-26
AU2019286795A1 (en) 2021-01-28
BR112020025443A2 (pt) 2021-03-16
WO2019238882A1 (en) 2019-12-19
PH12020552232A1 (en) 2021-06-28
CA3102483A1 (en) 2019-12-19
JP2021535733A (ja) 2021-12-23
TW202003560A (zh) 2020-01-16
US20240190953A1 (en) 2024-06-13
DOP2020000245A (es) 2021-10-31
SG11202011782XA (en) 2020-12-30
US11084874B2 (en) 2021-08-10
EA202092668A1 (ru) 2021-05-18
DOP2024000220A (es) 2025-02-28
US20200031918A1 (en) 2020-01-30
CR20210009A (es) 2021-06-21
JOP20200309A1 (ar) 2020-11-30
MX2020013583A (es) 2021-04-13

Similar Documents

Publication Publication Date Title
IL279356A (en) IL-11 antibodies
IL280780A (en) Anti-TIGIT antibodies
IL280013A (en) Anti-IL36R antibodies
IL279321A (en) Anti-SIRPalpha antibody
GB201809700D0 (en) IL-11 antibodies
IL275657A (en) C-KIT antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
IL278010A (en) Antibodies to galectin 10
GB201905150D0 (en) Ant-ige antibodies
GB201817172D0 (en) Antibody
GB202110263D0 (en) Anti-btla antibodies
IL277030A (en) Antibodies
IL284584A (en) Anti-tigit antibodies
SG11202100649VA (en) Anti-btla antibody
GB201811368D0 (en) Antibody
SG11202102114UA (en) Anti-klrg1 antibodies
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
PT4025612T (pt) Anticorpos anti-fucosil-gm1
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
HK40048053A (zh) Il-11抗体
SG11202105718TA (en) Modified antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)